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Abstract 
Objective: Amphibian skin secretions are an abundant source of bioactive peptides, 
some of which could be developed as candidate drugs. Among these natural peptides, 
cytolytic peptides have attracted the most attention given that they might replace 
conventional antibiotics and help deal with the problem of microbial resistance. This 
study discovered two bioactive peptides, Brevinin-1-PLr and Nigrocin-2-OV, from 
two species frogs, Rana palustris and Odorrana versabilis, respectively. Their 
antimicrobial, anticancer and hemolytic activities were also investigated. 
Methods: cDNA sequences encoding peptides were cloned from cDNA libraries 
constructed from the lyophilized secretions of Rana palustris and Odorrana versabilis. 
By reversed-phase HPLC and MS/MS fragmentation sequencing, the encoded novel 
peptides, named Nigrocin-2-OV and Brevinin-1-PLr, were identified in skin 
secretions and their structures were confirmed. Replicates of both peptides were 
produced through solid phase peptide synthesis. Their antimicrobial and anticancer 
activity was studied against three types of microorganisms (S. aureus, C. albicans, 
and E. coli) and five cancer cell lines (NCI-H157, PC-3, MDA-MB-435s, MCF-7, and 
U251MG). Their hemolytic activity was investigated using whole horse blood. 
Results: In this research, cDNA sequences encoding two novel 24-mer peptides were 
cloned from cDNA libraries constructed from the lyophilized skin secretions of Rana 
palustris and Odorrana versabilis. Both of the peptides had the strongest inhibitory 
effect against C. albicans, and IC50 values against five cancer cell lines were all under 
6 µM. 
Conclusions: Nigrocin-2-OV and Brevinin-1-PLr had the strong ability to inhibit the 
proliferation of studied microorganisms and tumor cell lines, with slight hemolytic 
activity. Compared with Brevinin-1-PLr, Nigrocin-2-OV exhibited higher 
antimicrobial and anticancer activity but slightly higher hemolytic activity. 
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Introduction 
Natural products have been gaining attention in recent years as a source of agents for 
treating many chronic diseases, especially in the development of anti-infection and 
anticancer drugs. Natural peptides with various activities have been found in many 
different amphibian species, and there is a clear relationship between frog skin 
peptides and their associated ability against pathogens.1,2 Generally, frog skin peptides 
are divided into two types according to their different bioactivities: cytolytic peptides 
and peptides with pharmacological activities.2 
With many lysine residues, antimicrobial peptides (AMPs) are cationic, which allows 
them to interact strongly with anionic phospholipids of bacterial membranes and 
eukaryotic cell membranes, such as cancer cells and erythrocytes.3 
The Ranidae family has the widest distribution among all frog families. These frogs 
are found on nearly all continents, except for Antarctica, and their living conditions 
vary from aquatic environments to more arid terrain.4 
Odorrana versabilis, the Chinese bamboo leaf odorous frog, is a species of frog in the 
Ranidae family that originates from China.5The North American pickerel frog (Rana 
palustris) is widely distributed in the United States and Canada.6 
As Conlon et al. have stated, the taxonomic classification of Rana frogs is quite 
difficult because of slight morphological differences and overlapping distributions of 
several species. In consideration of AMP structural variations among species of ranid 
frogs, molecular heterogeneity might be helpful for taxonomic and phylogenetic 
purposes.7 However, O. versabilis has been demonstrated to be the first major 
exception to this classification method. If the primary structures of frog skin peptides 
were used as a criterion for species classification, this species of frog should be 
counted as a North American species rather than Eurasian, according to Chen et al.5 In 
this study, the two frog species were selected and their novel skin secretion peptides 
examined to confirm this conclusion and further study their related bioactivities. 
Instead of a traditional animal-sacrifice method, secretions containing peptides were 
collected from frog skin surfaces in an animal-friendly manner, by the use of a 
pharmacological mediator or by a mild electrical shock, commonly applied in the 
laboratory.8 Granular gland secretions that contain many peptides, cytosolic 
components, and genetic materials, are released by serous cells of frog skin 
compressed under adrenergic stimulation.9 
Frog skin peptides are normally biosynthesized as prepropeptides. In amphibians, 
these precursors commonly display a tripartite structure, including a signal, spacer, 
and bioactive peptide.2The highly conserved features of the precursors of skin AMPs 
are most evident within the signal peptide domains.10The conserved region in the 
signal peptide sequence provides a basis for using a degenerate primer design in 
“shotgun” cDNA cloning, which is a method developed by Tianbao Chen’s 
laboratory.11 
Given that multidrug resistant super bacteria (superbugs) having emerged across the 
world and microbial resistance development appearing to be almost unstoppable, 
there exists an urgent need for novel antimicrobial agents. Natural peptides from a 
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new biological source with antimicrobial activity might be regarded as a solution to 
the resistance problem and represent a class of new therapeutic agents.12 
The mechanisms of anticancer and antimicrobial activities might be almost the same 
because the outer membrane surfaces of both cancer cells and pathogenic bacteria 
have above normal densities of negative charges, which make it easier for interactions 
with cationic peptides.13 Cancer remains a major cause of death, but current 
therapeutic methods, such as chemotherapy and surgery, have relatively low success 
rates and the risk of reappearance. Anticancer peptides have been developed to be 
drugs with higher selectivity for cancer cells and lower harmful effects on healthy 
tissues.14 
This study described the structural and functional characterization of two novel 
bioactive peptides with antimicrobial and anticancer activities from the defensive skin 
secretions of the Chinese bamboo leaf odorous frog (O. versabilis) and the North 
American pickerel frog (R. palustris), named Nigrocin-2-OV and Brevinin-1-PLr, 
respectively. The open-reading frames of cDNA encoding these peptides’ biosynthetic 
precursor were deduced following RACE-PCR cloning from skin cDNA libraries. 
Once full structural characterization was achieved, the protein bioactivities were 
determined and bioinformatic analyses performed. 
This study aimed to discover novel peptides with potential as candidates for 
antimicrobial and anticancer drugs. In addition, a goal was to discover the possible 
presence of similar primary structural peptides in these two frog species to confirm 
that peptide primary structures can be used to determine frog species relationships that 
might need to be better defined. 
Materials and Methods 
Specimen biodata and secretion collecting 
Adult specimens of O. versabilis (n=3) were caught in Hainan Province, the People’s 
Republic of China, and were settled into a vivarium at the Institute of Biotechnology, 
University of Fuzhou, for 4 months prior to secretion harvesting. Adult specimens of 
R.palustris (n=4) were purchased from the United States and raised in a 
purpose-designed amphibian facility at 18–25°C under a 12h/12h, light/dark cycle for 
4 months prior to secretion harvesting. The frogs were fed multivitamin-loaded 
crickets 3 times per week. Mild electrical stimulation (5V, 100 Hz, and 140 ms pulse 
width; C.F. Palmer, UK) was used to induce glands in the skin to produce defensive 
secretions, by moving a platinum electrode over moistened frog dorsal skin for 10 s 
duration. The skin secretions were washed from the frogs’ dorsal surface using 
deionized water, and the collections then frozen in liquid nitrogen, lyophilized in an 
Alpha1-2/LD freeze dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode, 
Germany), and stored at −20°C before use. Sampling of skin secretion was performed 
under UK Animal (Scientific Procedures) Act 1986, project license PPL 2694, issued 
by the Department of Health, Social Service and Public Safety, Northern Ireland. 
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Nucleotide sequence determination of the bioactive peptide 
precursor using “shotgun” cloning 
Through the process of shotgun cloning, the sequences of some of mRNAs present in 
lyophilized skin secretions were identified. 
A Dynabeads® mRNA DIRECT™ Kit (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) was employed to isolate mRNA from lyophilized skin secretion. Five-mg 
samples from lyophilized skin secretions were separately dissolved in 1 mL of 
lysis/binding buffer. Polyadenylated mRNA was isolated using magnetic oligo-dT 
beads, as described by the manufacturer, and reverse-transcribed. The cDNA was 
subjected to 3’-RACE procedures to obtain full-length prepro-brevinin nucleic acid 
sequence data using a BD Smart RACE cDNA Amplification Kit (Clontech Inc., 
Mountainview, CA, USA), essentially as described by the manufacturer. Briefly, the 
3’-RACE reactions employed a NUP primer (supplied with the kit) and a degenerate 
sense primer pool (S1:5’-GAWYYAYYHRAGCCYAAADATG-3’) that was designed 
to a highly conserved domain of the 5’-untranslated region of a previously 
characterized homologous peptide cDNA from Rana species.15In the first stage, 
samples were incubated at 96 °C for 1 minute, for initial denaturation. In the second 
stage, samples were incubated for 40 cycles of three steps: first, at 96 °C for 20 
seconds for denaturation; then, 55 °C for 10 seconds for annealing; and finally, 60 °C 
for 4 minutes for extension. In the last stage, the sample was incubated at 72 °C for 10 
minutes, as the final extension. The samples through these stages were incubated in 
the PCR machine at 4 °C. PCR products were gel-analyzed and purified applying an 
Omega E.Z.N.A.® Cycle Pure Kit (Omega Bio-tek, Inc., Norcross, GA, USA), cloned 
using a pGEM Easy Vector System II (Promega Corp., Madison, WI, USA), and 
sequenced usinga Big Dye® Terminator v 3.1 Cycle Sequencing Kit (Applied 
Biosystems/MDS SCIEX, Concord, ON, Canada).Finally, capillary electrophoresis 
and data analysis of the samples were performed. 
Peptidomic studies and employed analytical techniques 
Lyophilized skin secretions (5 mg) were dissolved in 1 mL of solution A (TFA/water, 
0.05/99.95, v/v) and clarified of microparticulates by centrifugation. The supernatant 
was subjected to RP-HPLC using a Cecil Adept CE4200 HPLC system (Amersham 
Biosciences, Inc., Piscataway, NJ, USA) employing an HPLC column (LUNA C-5 
preparative column, 250 × 10mm, Phenomenex Inc., Torrance, CA, USA) and 
Powerstream HPLC software, with the aid of a Waters 2489UV/Visible detector and 
1525 Binary HPLC pump (Waters Corp., Milford, MA, USA). A gradient elution 
format was used, going from 100% solution A (TFA/water,0.05/99.95, v/v) to 100% 
solution B (TFA/water/acetonitrile, 0.05/19.95/80, v/v) over a period of 240 minutes 
at a flow rate of 1 mL/min and the detector wavelength set at λ = 214 nm to detect 
peptide bonds. The molecular masses of detected polypeptides in each 
chromatographic fraction were further analyzed using MALDI-TOF MS, in positive 
detection mode, using CHCA as the matrix. Internal mass calibration of the 
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instrument with known standards established the mass determination accuracy within 
a deviation of 0.1%.The peptide with a mass coincident with those predicted from 
cloned precursor cDNAs were subjected to primary structural analysis by MS/MS 
fragmentation sequencing using an LCQ™ Fleet ion-trap mass spectrometer (Thermo 
Fisher Scientific Inc.) with an ESI ion source. 
Chemical synthesis of a novel peptide using solid phase 
peptide synthesis 
The activity of Nigrocin-2-OV and Brevinin-1-PLr, the peptide sequence coincident 
with the precursor cloned cDNAs were chemically synthesized by solid-phase Fmoc 
chemistry using a PS4 automated solid-phase synthesizer (Protein Technologies, Inc., 
Tuscon, AZ, USA). The peptides were separated from the synthesized resin and 
side-chain protection groups using a cleavage cocktail (95% TFA, 2.5% TIPS, and 
2.5% deionized water). Then, the peptides were treated with diethyl ether and stirring 
to form disulphide bonds. The synthesized peptides were analyzed by RP-HPLC and 
MALDI-TOF to verify their purity and structural reliability. 
Antimicrobial susceptibility tests of two types of peptides 
The antimicrobial activity of these novel peptides was assessed using three kinds of 
microorganisms, including Gram-negative bacterium Escherichia coli (NCTC 10418), 
Gram-positive bacterium Staphylococcus aureus (NCTC 10788), and yeast Candida 
albicans (NCPF 1467). The microorganisms were cultured in Muellar Hinton Broth 
(MHB) overnight (generally 16–20 hours) in an orbital incubator at 37 °C and 
150–200 rpm. A 500 µL volume of a culture was transferred to 20 mL of pre-warmed 
MHB for subculture until the microorganism attained log phase growth. The log 
phase optical densities of S. aureus, C. albicans, and E. coli were 0.25, 0.15, and 0.4 
respectively, detected at 550 nm using a UV spectrophotometer (CO7000 Medical 
Colorimeter, Biochrom Ltd., Cambridge, United Kingdom). Nigrocin-2-OV and 
Brevinin-1-PLr were prepared with PBS (Sigma-Aldrich, Inc., St. Louis, MO, USA) 
to reach a concentration of 512 × 102 mg/L (20 mM). This stock solution was then 
double diluted with the same solvent to achieve gradient peptide solutions. A specific 
concentration of peptide solution (1 µL) was added to a 96-well plate with seven 
replicates. Then, the bacterial subculture solution was diluted with sterilized MHB to 
reach a final concentration between 1 × 105 and 1 h 106 cfu/mL. This diluted 
subculture solution was used to dilute each peptide solution and added to growth 
control lines to produce 100 µLin each well. Sterilized MHB (100 µL) was used as 
negative control. The plates were incubated at 37°C overnight and the MIC values 
detected at λ = 550 nm. Peptides with inhibitory ability were further tested to observe 
their MBC values.  
Hemolytic activity of novel peptides 
Whole horse blood was used to test peptide hemolytic activity. Fresh whole horse 
blood (2–10 ml) was placed into a 50-mLcentrifuge tube and centrifuged to remove 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
the supernatant. The cell pellet was gently dispersed in 30 mL of PBS to wash the red 
blood cells (RBC) and recentrifuged until the supernatant ran clear. The clear 
supernatant was then discarded and 50 mL PBS added to the washed RBC to form a 
suspension. Each peptide was weighed to prepare a 512 × 2 mg/L (0.4 mM) peptide 
stock solution in PBS. Then, the stock solution was double diluted with sterilized PBS 
to produce gradient peptide solutions. 
For each concentration, quintuplicate volumes of 200 µL of peptide solution were 
added into 1.5-mLtubes. Then, 200 µL of RBC suspension was added to each tube. 
PBS and 1% Triton X-100 (Sigma-Aldrich, Inc.) were regarded as negative and 
positive controls, respectively. All tubes were incubated at 37°C for 2 hours and then 
centrifuged at 930×g for 5 minutes. Supernatants were added into a 96-well-plate 
(ThermoFisher Scientific Inc.) and the absorbance detected at 550 nm with an 
ELx808TM Absorbance Microplate Reader (BioTek Instruments, Inc., Winooski, VT, 
USA). 
The half maximal hemolytic concentration (HC50) values were analyzed with the aid 
of GraphPad Prism 6.0 software. 
Cell culture experiment and MTT cell viability assay for 
assessing anticancer activity of novel peptides 
Bioactivity screening of anticancer cell activity was performed using an MTT cell 
viability assay on five types of human cancer cell lines: NCI-H157, PC-3, 
MDA-MB-435s, MCF-7, and U251MG. The different cancer cell types were cultured 
using appropriate media, with RPMI 1640 Medium used to culture NCI-H157 and 
PC-3 and DMEM medium used to culture other three types of cancer cells.  
These cancer cell lines were cultured with serum-containing medium 
(medium/FBS/P-S, 100/10/1, v/v) in a 37°C and 5% CO2 incubator and the medium 
renewed every two days. When grown appropriately, cell lines should be subcultured 
to prevent cultures from dying. he peptide anticancer activity was tested by seeding 
cancer cells (100 µL) in 96-well plates, in quintuplicate, until they reached a 
concentration of 5000 cells/well, and the plates placed in a 37 °C incubator under 5% 
CO2 for 24 hours. Then, the culture medium was replaced with serum-free medium to 
starve the cancer cells for 6–12 hours. Peptide was dissolved in DMSO to obtain a 
10-2M stock solution, and gradient peptide concentration solutions (10-4 M to10-9 M) 
produced using serum-free medium. DMSO was 100-fold diluted by serum-free 
medium as a vehicle control, and serum-free medium used as a growth control. The 
cell medium was replaced by peptide and control solutions, and the plates incubated 
for 24 hours in a challenge peptide solution. Cell viability was determined by the 
reduction of MTT to its insoluble formazan. After 24 hours incubation, 10 µL of MTT 
(5 mg/mL in PBS) was added to each well and the plates further incubated for 4–6 
hours. After removing the liquid, 100 µl of DMSO was added to each well to dissolve 
the developed formazan crystals and the plates placed in an orbital shaker for 10 
minutes at maximum speed (250 rpm). The absorbance was measured using a Synergy 
HT plate reader (BioTek Instruments, Inc.) at 570nm. The half maximal inhibitory 
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concentration (IC50) values were analyzed with the aid of GraphPad Prism 6.0 
software. 
Results 
“Shotgun” cloning of novel peptide precursor-encoding 
cDNA 
After carrying out “shotgun” cloning with the aid of the Rana genus-specific 
degenerate primer pool and bioinformatic analysis using the NCBI-BLAST program, 
two bioactive peptide precursor-encoding cDNAs were cloned from the skin secretion 
library of O. versabilis and R. palustris and separately encoded single copies of a 
bioactive peptide named Nigrocin-2-OV and Brevinin-1-PLr, respectively (Fig. 1A 
and 1B). Both translated open-reading frames of the novel cloned cDNAs consisted of 
70 amino acid residues, including 22 amino acids of signal and spacer peptides, a 
processing site of Lys-Arg (K-R) for endoproteolytic cleavage, and a novel 24-mer of 
a mature peptide. The calculated mass and primary structures of these peptides are 
listed in Table 1. 
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Figure1 Nucleotide and translated open-reading frame amino acid sequence of 
biosynthetic precursor-encoding cDNA of Nigrocin-2-OV and Brevinin-1-PLr cloned 
from skin secretions derived from a library of O. versabilis and R. palustris, 
respectively. 
Note: The putative signal peptide was double-underlined, mature peptide was single-underlined, 
and stop codon was indicated by an asterisk. 
 
Table 1The calculated molecular mass data and primary structures for Nigrocin-2-OV 
and Brevinin-1-PLr. 
Peptides Mass calculated (ave., Da) Primary structure 
Nigrocin-2-OV 2563.246 FLPAIAGLAAKFLPKIFCAITKKC 
Brevinin-1-PLr 2549.219 FLPAIAGVAAKFLPKIFCAITKKC 
 
Identification and structural characterization of peptides in 
skin secretion 
The dried skin secretions of two kinds of frogs were subjected to reversed-phase 
HPLC fractionation and peptides in the column effluent detected at214 nm. The 
observed peptide molecular masses were coincident with the calculated molecular 
masses of Nigrocin-2-OV and Brevinin-1-PLr, derived from cloned skin biosynthetic 
precursor-encoding cDNAs, identified using MALDI-TOF mass spectrometry. It was 
found that the target peptides, Nigrocin-2-OV and Brevinin-1-PLr, located in the 127th 
and 126thfractions, respectively (Fig. 2). These two fractions were analyzed by 
electrospray ion-trap MS/MS fragmentation and the primary structures of the two 
putative peptides confirmed by MS/MS fragmentation sequencing (Table 2A and B). 
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Figure 2 Region of RF-HPLC chromatogram of skin secretion peptides from O. 
versabilis and R. palustris indicating elution position/retention time (peak 1 arrow) of 
the target peptides, Nigrocin-2-OV and Brevinin-1-PLr. 
 
Table 2 Electrospray ion-trap MS/MS fragmentation datasets derived from ions 
corresponding in molecular mass to the target peptides.  
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Note: Observed ions indicated in bold typeface and underlined. 
 
Antimicrobial assay of the novel peptides against tested 
microorganisms 
The antimicrobial activities of Nigrocin-2-OV and Brevinin-1-PLrwere tested by MIC 
assay on referenc estrains E. coli, S. aureus, and C. albicans. The growth of three 
types of microorganisms was inhibited by Nigrocin-2-OV and Brevinin-1-PLr to 
different extents, as shown in Table 3. 
Table 3 The mean MIC and MBC values for Nigrocin-2-OV and Brevinin-1-PLr 
against the three different test organisms. 
 
Organism MIC (µM) MBC (µM) 
Nigrocin-2-OV Brevinin-1-PLr Nigrocin-2-OV Brevinin-1-PLr 
S.aureus 3.12 6.28 49.94 50.22 
E.coli 12.49 25.11 99.88 50.22 
C.albicans 3.12 3.14 24.97 12.55 
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Hemolytic activity of the novel peptides 
The hemolytic activities of Nigrocin-2-OV and Brevinin-1-PLr were measured with 
the aid of whole horse blood. After triplicate experiments, both peptides were found to 
display hemolytic activity. The half maximal hemolytic concentrations (HC50) of 
Nigrocin-2-OV and Brevinin-1-PLr were 16 and 85 µM, respectively, as calculated 
using GraphPad Prism 6.0 software. 
MTT cell viability assay of novel peptides on tested cancer 
cell lines 
Nigrocin-2-OV and Brevinin-1-PLrwere found to have dose-dependent inhibitory 
effects on all tested cancer cell lines, as assessed using the MTT assay treated with 
peptide solutions ranging from 10-9M to 10-4 M and cultured over 24 hours. The half 
maximal inhibitory concentrations (IC50 values) of Nigrocin-2-OV and 
Brevinin-1-PLr against these types of cancer cells are shown in Table4. 
 
Table 4 The IC50 values of Nigrocin-2-OV and Brevinin-1-PLragainst five tested 
cancer cells lines. 
Cancer cell line IC50 (µM) 
Nigrocin-2-OV Brevinin-1-PLr 
NCI-H157 3.6 5.9 
PC-3 4.0 5.9 
MDA-MB-435S 4.3 3.5 
U251MG 4.8 3.9 
MCF-7 2.0 3.4 
 
Discussion 
By the means of NCBI BLAST, it was found that these two novel peptides, 
Nigrocin-2-OV and Brevinin-1-PLr, showed a high degree of similarity to peptides 
belonging to the brevinin-1 family, which is a typical antimicrobial peptide family 
given that they share some common features, such as a C-terminal disulphide-bridged 
cyclic heptapeptide, called “Rana box” cationic amino acids, and amphipathic ¢
-helical structures.1Zhou et al. have compared the open-reading frames and nucleic 
acid sequences between R. palustris and O. versabilis, and analogous peptides with 
high degrees of structural similarity have been found in these two species of frogs 
from different continents.10 
In this study, two novel bioactive peptides were discovered from the two frog species. 
The open-reading frames of skin AMPs were most evident within the signal peptide 
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domains, moderate within the acidic spacer peptide domains, and least within the 
mature peptide coding domains, which is in agreement with former studies. The 
primary structure of the mature peptides showed high identity, and there was only one 
different amino acid in the peptide primary structure, the 8th amino acid, which was 
lysine in Nigrocin-2-OV and valine in Brevinin-1-PLr, which indicated that using 
primary structure as criterion for taxonomy still needs to be improved. Both new 
peptides possessed a disulphide bridged cyclic heptapeptide (Cys18-(Xaa)4-Lys-Cys24) 
which played a crucial role in their antibacterial activities. 
Nigrocin-2-OV and Brevinin-1-PLr displayed an8-fold greater ability to inhibit S. 
aureus growth, compared to E. coli. Gehman has proposed that this preference might 
relate to higher amounts of negatively charged lipids in Gram-positive bacteria 
compared to Gram-negatives.16In addition to their binding affinity towards negatively 
charged membranes, other parameters also contribute to specific antibacterial effects, 
such as the complex ratio between surface charge and membrane order. In addition, 
bacterial membrane repair in nutrient-rich media and their ability to maintain against 
membrane damage might modulate growth inhibition potential.17 Thus, Hurst has 
thought that differences in MIC values might derive from a general Gram-negative 
bacterium, such as E. coli, having more potential to sustain membrane homeostasis 
than a Gram-positive bacterium, such as S. aureus.18 
Recently, some studies have illustrated that polycationic peptides possess synergistic 
properties with lipophilic and amphiphilic agents.19 In addition, as it was found here 
that Nigrocin-2-OV has synergistic effects with Norfloxacin against E. coli, the 
synergistic interactions between these novel polycationic peptides have the potential 
to serve as an adjuvant for antimicrobial chemotherapy.20 
Several AMPs have been reported to possess this obvious anticancer potential because 
of their cytotoxic activity against cancer cell growth. Previous research has indicated 
that cancer cells treated with frog skin peptides release the cytosolic enzyme lactate 
dehydrogenase, as a result of damage to plasma membrane integrity.21 In addition, 
apoptosis and necrosis are the two major mechanisms causing 
celldestruction.22Considering research on anticancer activities, these new peptides 
might have the ability to trigger apoptosis or necrosis of cancer cells as well. However, 
the specific mechanisms of how AMPs penetrate the cell membrane and induce 
apoptosis in treated cancer cells remains unknown.23 
As the peptide concentration that inhibits cancer cell growth might be lower than the 
concentration that inhibited the pathogen growth or RBC, this new peptide might have 
a relatively weaker ability for penetrating cell membranes. The ability to inhibit the 
growth of or to kill pathogens is determined by peptide structure, which is based on its 
amino acid sequence. The reason for the relatively higher cytolytic activity of 
Nigrocin-2-OV over Brevinin-1-PLr might be the different 8th amino acid, which 
produced different hydrophobicity and peptide spatial structure. 
In conclusion, some bioactivities of both peptides were initially evaluated, but other 
aspects await further investigation. The mechanisms of these peptides in inhibiting 
cancer cell growth remain unclear. 
Moreover, although these peptides were shown to have relatively low hemolytic 
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activity, this hemolytic ability would still be a negative factor for its use as a 
marketable drug. In this respect, more research is required to determine if 
modifications to the peptide can render it more cell-selective. 
There are about 100 therapeutic peptides (mostly innovative synthetics) on the market 
in the United States, Europe, and Japan.24 In 2012, there were 5 and 6peptides that 
gained market approval, respectively, in Europe and the United States, and there 
were128 peptide candidates in the clinical pipeline as drugs. Although great success 
has been achieved in the use of peptides in many clinical areas, the development of 
peptide drugs is still restricted by many factors. 
The route of peptide drug administration is one problem that is difficult to solve, 
especially for AMPs, as AMPs are hemolytic at concentrations at which they kill 
pathogens, which makes them almost impossible to deliver by intravenous injection. 
Modification of peptide chemical structures is a possible solution and, indeed, some 
AMPs have been modified to be more selective. 
Another problem is large-scale production. Peptide isolation from natural sources is 
not cost effective and can only be used for native peptide exploration. When it comes 
to manufacturing either native or modified cationic peptides, the natural approach is 
very costly. 
Mature regulations for peptide drug registration are also needed. Only one guideline 
specifically addresses peptides in the field of manufacturing, which shows there is an 
urgent need to improve drug administration to involve more information and guidance 
in peptide drugs. 
In addition, an increasing number of studies have illustrated that bacterial pathogens 
might resist AMPs.25 AMPs and AMP-resistance mechanisms are the result of highly 
dynamic co-evolutionary processes, but it remains unclear how adaptations in 
resistant microorganisms have influenced AMP evolution.26Therefore, if AMPs are to 
be developed as an alternative therapy to traditional antibiotics, more research on the 
molecular basis of bacterial resistance to AMPs is required to improve the 
understanding of the process and avoid resistant cases. 
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ionization (ESI); fluorenyl methoxycarbonyl (Fmoc); trifluoroacetic acid (TFA), triisopropylsilane 
(TIPS); phosphate buffered saline (PBS); National Centre for Biotechnology Information (NCBI); 
Basic Local Alignment Search Tool (BLAST); colony forming units (cfu); non-small cell lung 
cancer (NCI-H157); human prostate carcinoma (PC-3); melanoma (MDA-MB-435s); breast 
cancer non-tumorigenic mammary gland (MCF-7); human neuronal glioblastoma (U251MG); 
Roswell Park Memorial Institute (RPMI); Dulbecco’s Modified Eagle (DMEM); 
penicillin-streptomycin (P-S); fetal bovine serum (FBS); minimal inhibitory concentration (MIC); 
and minimal bactericidal concentration (MBC) 
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